CA1336825C - Use and agent for reducing the side effects of tnf - Google Patents
Use and agent for reducing the side effects of tnfInfo
- Publication number
- CA1336825C CA1336825C CA000598696A CA598696A CA1336825C CA 1336825 C CA1336825 C CA 1336825C CA 000598696 A CA000598696 A CA 000598696A CA 598696 A CA598696 A CA 598696A CA 1336825 C CA1336825 C CA 1336825C
- Authority
- CA
- Canada
- Prior art keywords
- paf
- web
- antagonist
- tnf
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000000694 effects Effects 0.000 title claims abstract description 14
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 claims abstract description 18
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 10
- SCSIRWUYQVAIRL-UHFFFAOYSA-N ac1miw90 Chemical compound C1=2CC(C(=O)N(CCC)CCC)CC=2SC(N2C(C)=NN=C2CN=2)=C1C=2C1=CC=CC=C1Cl SCSIRWUYQVAIRL-UHFFFAOYSA-N 0.000 claims description 8
- FWYVRZOREBYLCY-UHFFFAOYSA-N bepafant Chemical compound C1C=2SC=3N4C(C)=NN=C4CN=C(C=4C(=CC=CC=4)Cl)C=3C=2CC1C(=O)N1CCOCC1 FWYVRZOREBYLCY-UHFFFAOYSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 206010054094 Tumour necrosis Diseases 0.000 claims description 3
- 102000018594 Tumour necrosis factor Human genes 0.000 claims description 3
- 108050007852 Tumour necrosis factor Proteins 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 2
- 229940102223 injectable solution Drugs 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract description 11
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 239000005557 antagonist Substances 0.000 description 7
- 239000013543 active substance Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- FGNAJWFZOBYZLR-UHFFFAOYSA-N 3h-[1,2,4]triazolo[4,3-a][1,4]diazepine Chemical compound N1=CC=CN2CN=NC2=C1 FGNAJWFZOBYZLR-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000010057 immune-inflammatory process Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- HNDGEYCCZGRMTN-UHFFFAOYSA-N thieno[3,2-f:4,5-f]bis[1]benzothiophene Chemical compound S1C2=CC=3SC=CC=3C=C2C2=C1C=C(SC=C1)C1=C2 HNDGEYCCZGRMTN-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Paper (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Separation Of Suspended Particles By Flocculating Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3816169A DE3816169A1 (de) | 1988-05-11 | 1988-05-11 | Verwendung und mittel zur verminderung der nebenwirkungen von tnf |
| DEP3816169.9 | 1988-05-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1336825C true CA1336825C (en) | 1995-08-29 |
Family
ID=6354207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000598696A Expired - Fee Related CA1336825C (en) | 1988-05-11 | 1989-05-04 | Use and agent for reducing the side effects of tnf |
Country Status (13)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3735525C2 (de) * | 1987-10-20 | 1997-02-20 | Korth Ruth Maria | Verfahren zur Bestimmung der Wirksamkeit von paf-Acether-Rezeptor-Antagonisten |
| GB8926611D0 (en) * | 1989-11-24 | 1990-01-17 | Xenova Ltd | Compound and its use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3786456T2 (de) * | 1986-10-16 | 1994-02-03 | Biogen Inc | Kombinationen von nekrose-tumor-faktoren und entzündungshemmenden mitteln für die behandlung von bösartigen und nicht bösartigen erkrankungen. |
-
1988
- 1988-05-11 DE DE3816169A patent/DE3816169A1/de not_active Withdrawn
-
1989
- 1989-05-01 KR KR1019890005809A patent/KR900017592A/ko not_active Withdrawn
- 1989-05-03 ES ES89107969T patent/ES2042864T3/es not_active Expired - Lifetime
- 1989-05-03 DE DE8989107969T patent/DE58901920D1/de not_active Expired - Lifetime
- 1989-05-03 AT AT89107969T patent/ATE78695T1/de not_active IP Right Cessation
- 1989-05-03 EP EP89107969A patent/EP0341558B1/de not_active Expired - Lifetime
- 1989-05-03 ZA ZA893259A patent/ZA893259B/xx unknown
- 1989-05-04 CA CA000598696A patent/CA1336825C/en not_active Expired - Fee Related
- 1989-05-05 DK DK220789A patent/DK220789A/da not_active Application Discontinuation
- 1989-05-05 IL IL90206A patent/IL90206A0/xx unknown
- 1989-05-05 HU HU892180A patent/HUT52381A/hu unknown
- 1989-05-05 AU AU34064/89A patent/AU614607B2/en not_active Ceased
- 1989-05-06 JP JP1113985A patent/JP2709139B2/ja not_active Expired - Lifetime
-
1992
- 1992-08-06 GR GR920401724T patent/GR3005387T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK220789A (da) | 1989-11-12 |
| JPH0276825A (ja) | 1990-03-16 |
| ZA893259B (en) | 1991-01-30 |
| DK220789D0 (da) | 1989-05-05 |
| DE3816169A1 (de) | 1989-11-23 |
| IL90206A0 (en) | 1989-12-15 |
| ATE78695T1 (de) | 1992-08-15 |
| EP0341558A2 (de) | 1989-11-15 |
| EP0341558A3 (en) | 1990-05-09 |
| AU3406489A (en) | 1989-11-16 |
| EP0341558B1 (de) | 1992-07-29 |
| GR3005387T3 (enrdf_load_stackoverflow) | 1993-05-24 |
| AU614607B2 (en) | 1991-09-05 |
| JP2709139B2 (ja) | 1998-02-04 |
| KR900017592A (ko) | 1990-12-19 |
| HUT52381A (en) | 1990-07-28 |
| DE58901920D1 (de) | 1992-09-03 |
| ES2042864T3 (es) | 1993-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2785349B2 (en) | Combination treatment of cancer | |
| PL193375B1 (pl) | Kompozycja zawierająca inhibitor kinazy tyrozynowej i środek do kastracji chemicznej i jej zastosowanie w terapii i do inhibitowania progresji raka prostaty oraz zastosowanie inhibitora kinazy tyrozynowej i środka do kastracji chemicznej do inhibitowania progresji raka prostaty | |
| CZ20031660A3 (cs) | Farmaceutický přípravek obsahující aspirin | |
| HU205713B (en) | Process for producing pharmaceutical compositions | |
| CN113453677A (zh) | 用于治疗急性心房颤动的舒卡定施用 | |
| ES2251715T3 (es) | Suspensiones inyectables de efecto prolongado de un analogo de lhrh y un procedimiento para su preparacion. | |
| JP2002518449A (ja) | 高血中コレステロールを治療する組成物および方法 | |
| CA1336825C (en) | Use and agent for reducing the side effects of tnf | |
| CA2408797A1 (en) | Treatment of breast cancer | |
| EP0667349B1 (en) | Depression remedy | |
| JP3587851B2 (ja) | Ｔｎｆ誘発病状の治療におけるベンジダミンの使用 | |
| JPH07242544A (ja) | 抗腫瘍剤 | |
| US6306901B1 (en) | Agent for prophylaxis and therapy of diseases | |
| US4391809A (en) | Methods for treating psoriasis | |
| CA2684171C (fr) | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens | |
| JPH03505447A (ja) | アミオダロンと、ニトロ誘導体、特にイソソルビト二硝酸と、必要に応じてさらにβ―遮断薬とを含む心臓保護効果のある医薬組成物 | |
| HU203666B (en) | Process for producing pharmaceutical compositions containing dipyridamol for improving antiviral activity of interferone-alpha | |
| JP2609882B2 (ja) | 脱髄性疾患治療薬 | |
| CN119607012A (zh) | 舞茸多糖d组分或其衍生物在制备抗精神分裂症的药物中的应用 | |
| EP1199077A1 (en) | Stable compositions of oxapenem-3-carboxylic acids by Co-lyophilisation with pharmaceutical carriers | |
| CZ175397A3 (en) | Kit used for treating or prevention of osteoporosis | |
| JPH07505885A (ja) | 血小板活性化因子拮抗薬組成物およびそれによるインターロイキン−２誘発肺損傷の治療方法 | |
| JPH051244B2 (enrdf_load_stackoverflow) | ||
| JP2022552336A (ja) | 造血器悪性腫瘍を治療するための併用療法 | |
| CA2472160A1 (en) | Quinazolinone compounds in combined modalities for improved cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |